← brief for 2026-08-11 · Slowing decline

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Trial No results yet Not peer reviewed

Key takeaways

This large trial tests a new drug, BI 690517, added to empagliflozin in adults with chronic kidney disease who are at risk of getting worse. People with and without type 2 diabetes can join, including those already on standard kidney medicines. It is starting now, so there are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: Apogee Clinical Research · Southwest Kidney Institute · National Heart Institute · Florida Kidney Physicians LLC · Total Research Group, LLC · Emory University School of Medicine

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-08-10
https://clinicaltrials.gov/study/NCT06531824